241 related articles for article (PubMed ID: 27531673)
1. Increased expression of Trpv1 in peripheral terminals mediates thermal nociception in Fabry disease mouse model.
Lakomá J; Rimondini R; Ferrer Montiel A; Donadio V; Liguori R; Caprini M
Mol Pain; 2016; 12():. PubMed ID: 27531673
[TBL] [Abstract][Full Text] [Related]
2. Pain related channels are differentially expressed in neuronal and non-neuronal cells of glabrous skin of fabry knockout male mice.
Lakomá J; Rimondini R; Donadio V; Liguori R; Caprini M
PLoS One; 2014; 9(10):e108641. PubMed ID: 25337704
[TBL] [Abstract][Full Text] [Related]
3. L-Acetylcarnitine causes analgesia in mice modeling Fabry disease by up-regulating type-2 metabotropic glutamate receptors.
Formaggio F; Rimondini R; Delprete C; Scalia L; Merlo Pich E; Liguori R; Nicoletti F; Caprini M
Mol Pain; 2022; 18():17448069221087033. PubMed ID: 35255745
[TBL] [Abstract][Full Text] [Related]
4. αCGRP is essential for algesic exocytotic mobilization of TRPV1 channels in peptidergic nociceptors.
Devesa I; Ferrándiz-Huertas C; Mathivanan S; Wolf C; Luján R; Changeux JP; Ferrer-Montiel A
Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18345-50. PubMed ID: 25489075
[TBL] [Abstract][Full Text] [Related]
5. Characterization of small fiber pathology in a mouse model of Fabry disease.
Hofmann L; Hose D; Grießhammer A; Blum R; Döring F; Dib-Hajj S; Waxman S; Sommer C; Wischmeyer E; Üçeyler N
Elife; 2018 Oct; 7():. PubMed ID: 30328411
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive and differential long-term characterization of the alpha-galactosidase A deficient mouse model of Fabry disease focusing on the sensory system and pain development.
Üçeyler N; Biko L; Hose D; Hofmann L; Sommer C
Mol Pain; 2016; 12():. PubMed ID: 27145802
[TBL] [Abstract][Full Text] [Related]
7. TRPV1 expression level in isolectin B₄-positive neurons contributes to mouse strain difference in cutaneous thermal nociceptive sensitivity.
Ono K; Ye Y; Viet CT; Dang D; Schmidt BL
J Neurophysiol; 2015 May; 113(9):3345-55. PubMed ID: 25787958
[TBL] [Abstract][Full Text] [Related]
8. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
[TBL] [Abstract][Full Text] [Related]
9. Fabry disease.
Toyooka K
Handb Clin Neurol; 2013; 115():629-42. PubMed ID: 23931807
[TBL] [Abstract][Full Text] [Related]
10. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease.
Bangari DS; Ashe KM; Desnick RJ; Maloney C; Lydon J; Piepenhagen P; Budman E; Leonard JP; Cheng SH; Marshall J; Thurberg BL
Am J Pathol; 2015 Mar; 185(3):651-65. PubMed ID: 25553976
[TBL] [Abstract][Full Text] [Related]
11. Stratification of Fabry mutations in clinical practice: a closer look at α-galactosidase A-3D structure.
Rickert V; Wagenhäuser L; Nordbeck P; Wanner C; Sommer C; Rost S; Üçeyler N
J Intern Med; 2020 Nov; 288(5):593-604. PubMed ID: 32583479
[TBL] [Abstract][Full Text] [Related]
12. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
13. Expression of genes and their responses to enzyme replacement therapy in a Fabry disease mouse model.
Park ES; Choi JO; Park JW; Lee MH; Park HY; Jung SC
Int J Mol Med; 2009 Sep; 24(3):401-7. PubMed ID: 19639234
[TBL] [Abstract][Full Text] [Related]
14. Ion channels and pain in Fabry disease.
Weissmann C; Albanese AA; Contreras NE; Gobetto MN; Castellanos LCS; Uchitel OD
Mol Pain; 2021; 17():17448069211033172. PubMed ID: 34284652
[TBL] [Abstract][Full Text] [Related]
15. Bradykinin Induces TRPV1 Exocytotic Recruitment in Peptidergic Nociceptors.
Mathivanan S; Devesa I; Changeux JP; Ferrer-Montiel A
Front Pharmacol; 2016; 7():178. PubMed ID: 27445816
[TBL] [Abstract][Full Text] [Related]
16. Neuropathic pain in a Fabry disease rat model.
Miller JJ; Aoki K; Moehring F; Murphy CA; O'Hara CL; Tiemeyer M; Stucky CL; Dahms NM
JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563343
[TBL] [Abstract][Full Text] [Related]
17. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
18. An in vitro model of Fabry disease.
Shu L; Murphy HS; Cooling L; Shayman JA
J Am Soc Nephrol; 2005 Sep; 16(9):2636-45. PubMed ID: 16033856
[TBL] [Abstract][Full Text] [Related]
19. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
[TBL] [Abstract][Full Text] [Related]
20. The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain.
Choi L; Vernon J; Kopach O; Minett MS; Mills K; Clayton PT; Meert T; Wood JN
Neurosci Lett; 2015 May; 594():163-8. PubMed ID: 25697597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
